COVID-19 vaccine effective among patients with psoriatic disease
Click Here to Manage Email Alerts
PHILADELPHIA — The efficacy of COVID-19 vaccinations is similar in patients with psoriatic disease compared non-psoriatic controls, according to data presented at ACR Convergence 2022.
“In this study, we assessed the effectiveness of COVID-19 vaccination on infections and COVID-19 related hospitalizations in patients with psoriatic disease and non-psoriatic controls, and also assess the association of immune mediated medications on these COVID-related outcomes,” Lihi Eder, MD, PhD, clinician-scientist at the Women’s College Research Institute and associate professor of medicine at the University of Toronto, said during a presentation.
The population-based study utilized data from the ClalitHealth Services in Israel, and included patients with a diagnosis of psoriasis and/or psoriatic arthritis who were matched in a 1:5 ration with non-psoriatic controls. Two separate analyses occurred over two periods, according to the poster. Period one ran from December 2020 to August 2021 and included the initiation of COVID-19 vaccines until the initiation of booster vaccines. Period two ran from August 2021 to December 2021 and included the initiation of booster vaccines until the end of study. The primary outcomes were SARS-CoV-2 PCR positivity and hospitalization for COVID-19.
The analysis included 128,754 patients with psoriatic disease, including 5,934 who were SARS-CoV-2 positive and 315 who were hospitalized; and 600,439 controls, which included 26,292 controls who were SARS-CoV-2 positive and 1,127 who were hospitalized.
Eder and colleagues reported similar vaccine effectiveness for SARS-CoV-2 infection, including booster vaccine effectiveness, and hospitalizations between patients with psoriatic disease and controls. Moreover, after controlling for systemic immune mediated therapies, vaccines remained effective for SARS-CoV-2 infections and hospitalizations for patients with psoriatic disease.
However, a higher risk for SARS-CoV-2 infection was associated with the use of etanercept (Enbrel, Amgen) and treatment with JAK inhibitors was associated a with higher risk for hospitalizations.
When analyzing patients with PsA compared with patients with psoriasis alone, patients with PsA did not have a higher risk for infection or hospitalization, according to the poster.
“This study found that [the] COVID-19 vaccine has similar effectiveness in patients with psoriatic disease to that seen in non-psoriatic controls, and that the risk of COVID-19 hospitalizations among psoriatic disease patients may be influenced by certain immune-modulated therapies,” Eder said.
Collapse
Eder L, et al. Abstract 0389. Presented at: ACR Convergence 2022; November 11-14, 2022; Philadelphia (hybrid meeting).
Click Here to Manage Email Alerts